Redhill Biopharma Ltd
NASDAQ:RDHL
Redhill Biopharma Ltd
NASDAQ:RDHL
Price:
1.025
USD
-0.49%
Market Closed
Market Cap:
$5.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Redhill Biopharma Ltd
Other Long-Term Assets
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Redhill Biopharma Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
Other Long-Term Assets
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Other Long-Term Assets
$2.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
0%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Other Long-Term Assets
$1.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Other Long-Term Assets
$311k
|
CAGR 3-Years
46%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Other Long-Term Assets
$439k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Other Long-Term Assets
₪7.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
No Stocks Found
Redhill Biopharma Ltd
Glance View
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.
RDHL
Intrinsic Value
9.301
USD
Undervaluation 89%
See Also
What is Redhill Biopharma Ltd's Other Long-Term Assets?
Other Long-Term Assets
0
USD
0
USD
Based on the financial report for Jun 30, 2025, Redhill Biopharma Ltd's Other Long-Term Assets amounts to 0 USD.
